Amid intensifying ADC competition, Aimed Bio bets on clinical initiative < Bio < Article - KBR
Technology Transfer News
“Preclinical technology transfer alone is insufficient,” Aimed Bio CEO Her Nam-gu said. “It's now time to demonstrate the company's next phase through ...
